Merck’s $6 Billion Cancer Power Move: The Terns Pharma Deal That Rewrites Pharma’s Post-Keytruda Playbook

Merck nears a $6bn all-cash acquisition of Terns Pharma and its CML drug TERN-701. Here’s the full strategic picture—what it means for patients, investors, and Big Pharma’s 2026 M&A wave.

The ink isn’t dry. The deal isn’t signed. But the logic behind Merck’s reported $6 billion pursuit of Terns Pharmaceuticals is already one of the clearest strategic narratives in modern pharma — a $30 billion time bomb called Keytruda, and the urgent search for what comes after.

Merck is nearing a roughly $6 billion all-cash deal to acquire Terns Pharmaceuticals, the Financial Times reported on Tuesday, citing people familiar with the matter. MarketScreener Talks between the two companies are at an advanced stage, and a deal could be reached within days. MarketScreener The target: a Foster City, California clinical-stage company whose lead drug is quietly generating the most excitement in blood cancer treatment since a Novartis blockbuster redrew the CML landscape a generation ago.

For Merck, this is not merely another acquisition. It is an act of strategic triage — and perhaps the most scientifically precise bet the Kenilworth giant has placed since it licensed pembrolizumab from Schering-Plough in 2009 and renamed it Keytruda.

Why Keytruda’s Patent Cliff Is the Most Watched Clock in Global Pharma

To understand why Merck is willing to pay a premium for a drug that has never been approved — and has barely cleared Phase 1 — you must first understand the existential arithmetic of the world’s best-selling medicine.

Keytruda is slated for a loss of exclusivity in 2028, and a growing pipeline of biosimilars is already lining up to take a shot at the drug’s massive market. Fierce Pharma The cancer therapy brought the company $29.5 billion last year C&EN, representing nearly half of Merck’s total revenue. CEO Robert Davis sees about $70 billion in commercial opportunities by the mid-2030s and has described the current pipeline as one of the “deepest and broadest” Merck has ever had. Stocktwits

That confidence, however, must be earned — deal by deal, trial by trial. Merck has predicted Keytruda will collect $35 billion in peak annual sales in 2028, the same year the drug will face an expected patent cliff. Fierce Pharma After that, biosimilar entrants from Samsung Bioepis, Amgen, and Indian manufacturers are expected to erode revenues precipitously. The company needs successors, and it needs them now.

The response has been an M&A blitz of rare intensity. Merck has accelerated dealmaking in recent months, snapping up Verona Pharma for $10 billion and Cidara Therapeutics for $9.2 billion last year Investing.com, adding a first-in-class COPD therapy and a long-acting flu antiviral, respectively. Merck has been building up its late-stage drug pipeline since 2021 and has signed several deals to broaden its portfolio. U.S. News & World Report February brought yet another structural bet: Merck split its core pharmaceutical business in two — one housing its oncology portfolio and the other including all non-cancer medicines Fierce Pharma — a move analysts interpreted as pre-positioning for either a spin-off, a focused acquisition strategy, or both.

The Terns deal, if confirmed, is the latest and sharpest arrow in that quiver.

TERN-701: The Drug That Has CML Specialists Talking in Superlatives

Chronic myeloid leukemia is not a common cancer. Roughly 8,900 new cases are diagnosed in the United States each year. But it is a high-value market — heavily treated with expensive precision medicines — and Terns has built its entire identity around the conviction that the next generation of CML therapy remains conspicuously unfinished.

Terns’ lead cancer drug candidate is TERN-701, which is in development for the treatment of relapsed/refractory CML under the Phase 1 CARDINAL trial. RTTNews The drug’s mechanism is where the science gets genuinely interesting: TERN-701 is active at the myristate pocket of BCR-ABL1, providing it with 10,000 times greater selectivity than active-site tyrosine kinase inhibitors. Onclive

That molecular precision matters enormously in a disease defined by acquired resistance. The current standard of care for later-line CML, Novartis’s asciminib (Scemblix), was itself an allosteric BCR-ABL inhibitor that redrew treatment algorithms when it won approval — but resistance mutations and tolerability issues mean a significant portion of patients still cycle through therapies without achieving durable molecular response. Early study results suggest that TERN-701 could be a successor to Novartis’s blockbuster Scemblix. Statnews

The CARDINAL trial data, presented at the American Society of Hematology annual meeting in December 2025, was what turned heads. At the recommended Phase 2 dose of at least 320 mg once daily, the overall 24-week major molecular response rate was 80% among efficacy-evaluable patients with more than 24 weeks of follow-up. Onclive For patients maintaining MMR, the rate held at 100%. Ternspharma

The safety profile is equally notable. The majority of treatment-emergent adverse effects were low grade, with no apparent dose relationship. Rates of cytopenias were generally low, with less than 10% Grade 3 thrombocytopenia and neutropenia. Onclive No dose-limiting toxicities were observed up to the maximum dose of 500mg QD. Ternspharma

For heavily pre-treated patients — many of whom had previously received asciminib, ponatinib, and investigational next-generation therapies — these numbers are not merely encouraging. They are, by the standards of relapsed/refractory CML, remarkable. “Best-in-disease potential” is the phrase Terns itself has used, and the clinical data does not obviously contradict that claim.

The Valuation Calculus: What Does $6 Billion Actually Buy?

The all-cash deal is expected to value Terns at a premium to its market capitalization of about $5.3 billion. Investing.com That premium, while meaningful, is modest by the standards of 2025–2026 oncology M&A — a sector where bidding wars routinely push acquirers to 60–80% above last close.

Why the relative restraint? Several factors shape the math.

TERN-701 remains in Phase 1. There is no approved product, no commercial infrastructure, and no Phase 3 data. Pivotal trial results — the evidence that would trigger blockbuster valuations and genuine upside scenarios — are still at least two to three years away. For a drug targeting a relatively rare indication, the peak revenue ceiling, while lucrative, is bounded. Analysts covering the CML market typically model mature annual sales for a best-in-class next-generation allosteric inhibitor in the $2–4 billion range globally, depending on label breadth and first-line expansion.

At $6 billion all-cash, Merck is effectively paying two to three times peak sales estimates upfront — aggressive, but not irrational when the acquirer is running a multi-decade oncology platform and values de-risked, validated science over raw market speculation.

The deal also reflects Terns’ strategic leverage. Terns had cash runway into 2028 focused on advancing the CML program internally and partnering metabolic assets Ternspharma — meaning the company was not under existential financial pressure to sell. That negotiating position, combined with competitive interest from other potential suitors, likely shaped the final price.

The Broader Strategic Picture: Merck’s New Oncology Architecture

The Terns acquisition, viewed in isolation, reads as a sensible pipeline bolt-on. Viewed in the context of Merck’s full strategic reshaping, it takes on a different quality — the latest piece in what is becoming one of the most ambitious pharma rebuilding exercises since the post-Lipitor era.

Consider the deal sequencing. Merck’s $11.5 billion deal for Acceleron Pharmaceuticals added the pulmonary arterial hypertension therapy Winrevair; the Verona Pharma acquisition brought Ohtuvayre, a first-in-class COPD treatment; and the Cidara deal added CD388, a long-acting antiviral against all flu strains. Invezz Each transaction has shared a common logic: early enough in commercial life to offer genuine upside, but far enough along in clinical development to substantially de-risk.

TERN-701 fits that template — though the clinical-stage risk is somewhat higher than in those prior deals. What elevates the strategic rationale is the oncology division context. As part of the restructuring, Merck’s human-health business will be split into two — one housing its oncology portfolio and the other including all of its non-cancer medicines. U.S. News & World Report Citi analysts said the split would help to more clearly distinguish Merck’s mature oncology portfolio from its newer, acquisition-driven assets. U.S. News & World Report

Adding a potentially best-in-class CML asset directly strengthens the new oncology unit’s pipeline depth — a consideration that matters not only commercially, but also in how investors and potential partners value the separated entity. If Merck eventually pursues a spin-off or strategic transaction involving the oncology division, a richer pipeline commands a materially higher multiple.

There is also the question of platform. BCR-ABL inhibition in CML has historically served as a scientific and regulatory template for targeted therapies in adjacent hematological malignancies. If TERN-701’s allosteric mechanism proves transferable — to blast phase CML, to Philadelphia chromosome-positive ALL, or to other BCR-ABL-driven contexts — the addressable market expands substantially beyond the initial rare indication.

What It Means for Patients: Access, Pricing, and the CML Treatment Gap

Abstract strategy and valuation calculus exist in tension with a more human question: what does this deal mean for the roughly 30,000 Americans — and hundreds of thousands globally — currently living with CML?

On balance, consolidation under a well-capitalized major pharma is likely to accelerate the path to approval. Merck’s regulatory infrastructure, commercial relationships, and Phase 3 execution capability represent genuine accelerants for a drug that Terns, as a clinical-stage company, would have struggled to advance at comparable speed. The CARDINAL trial needs to expand into a full pivotal program; a major pharma’s resources materially compress that timeline.

The pricing question is less comfortable. Tyrosine kinase inhibitors for CML are already among the most expensive chronic disease therapies in the U.S. market. Novartis’s asciminib lists at over $200,000 annually. Should TERN-701 achieve approval — and the Phase 1 data suggests it is on track to try — it will enter a market where Merck will be under both commercial pressure to recoup its $6 billion investment and political pressure to justify the cost of a rare disease therapy.

The international access picture is sharper still. Keytruda may face “price setting” from the Inflation Reduction Act in 2026 C&EN, and the broader U.S.-China oncology R&D race is intensifying as Chinese biotechs, many partnered with or competing directly against Western majors, rapidly advance their own BCR-ABL and kinase inhibitor portfolios. A Merck-owned TERN-701 will need a global commercialization strategy that balances pricing sustainability in the U.S. against access in markets where affordability remains the defining constraint.

The 2026 M&A Wave: Terns as Precedent, Not Outlier

Industry-watchers have spent the past 18 months watching the pharma M&A pipeline with unusual intensity, and the Terns deal — if it closes — will not be the last deal of this kind in 2026. The conditions for a sustained acquisition wave remain firmly in place.

Patent cliffs are not unique to Merck. AstraZeneca, Bristol-Myers Squibb, and Pfizer all face meaningful revenue transitions in the latter half of the decade. Interest rates, while elevated versus the zero-rate era, remain manageable for investment-grade acquirers with strong cash generation. Biotech valuations, while partially recovered from the 2022–2023 trough, have not returned to the frothy heights that previously priced out strategic acquirers. That creates a window — perhaps 18 to 36 months — in which well-capitalized majors can acquire genuine clinical-stage innovation at multiples that may look cheap in retrospect.

The calculus changes if clinical-stage failures mount, or if the regulatory environment shifts adversely for rare oncology indications. But for now, the structural incentives point toward more deals, not fewer. Merck CEO Robert Davis said as much in February: “Our belief in our ability to have substantial growth once we get closer to the [loss of exclusivity] is as high as it’s ever been. And we’re not done.” Fierce Pharma

The Terns deal, at $6 billion, is arguably modest by the ambitions of that statement — a targeted bet on a validated mechanism in a well-understood disease, dressed in the clinical data that Big Pharma acquirers find most legible. What comes next in Merck’s dealmaking could be considerably larger.

Forward Scenarios: Three Possible Outcomes for TERN-701

Scenario 1 — Accelerated Approval Pathway: If TERN-701’s Phase 1 data is persuasive enough for Breakthrough Therapy Designation (which Terns has not yet obtained), Merck could potentially pursue an accelerated approval pathway using MMR as a surrogate endpoint — a strategy previously used for asciminib. A 2028–2029 approval timeline is not implausible. In this scenario, the deal looks like sharp value creation.

Scenario 2 — Pivotal Trial Success, Standard Path: The more likely route involves a full Phase 3 randomized controlled trial, standard FDA review, and approval in the early 2030s. In this scenario, TERN-701 becomes a useful but not transformative contributor to Merck’s oncology revenue — meaningful for patients, positive but not game-changing for Merck’s post-Keytruda financials.

Scenario 3 — First-Line Expansion: The real prize — the scenario that would vindicate the $6 billion price tag in full — is if TERN-701 demonstrates superiority or equivalence to standard-of-care in earlier lines of CML therapy. A first- or second-line label would multiply the addressable patient population by an order of magnitude, transforming a rare disease asset into a genuine oncology pillar.

The Bottom Line

The Merck–Terns deal is not, by the standards of 2025–2026 Big Pharma dealmaking, extraordinary in size. What makes it significant is its specificity. Merck is not buying a diversified biotech platform or hedging its bets across a sprawling pipeline. It is making a concentrated, scientifically defensible wager on one drug, one mechanism, and one disease — a bet that a next-generation allosteric BCR-ABL inhibitor with 80% major molecular response rates in heavily pre-treated patients represents exactly the kind of targeted, data-driven oncology innovation that commands a premium in any market cycle.

Whether TERN-701 ultimately delivers on its early clinical promise remains genuinely uncertain. Phase 1 data, however spectacular, does not guarantee Phase 3 success. Regulatory hurdles, competitive pressure from asciminib and emerging Chinese generics, and the perennial challenges of rare disease commercialization will all shape the eventual story.

But for the patients cycling through failed CML therapies — people who have exhausted three, four, even six prior tyrosine kinase inhibitors — the prospect of a new mechanism with a favorable safety profile and compelling molecular response rates is not a valuation abstraction. It is the news they have been waiting for.

Merck is betting $6 billion on the proposition that those patients deserve a better option. That, at its core, is the deal.

Key Deal Facts at a Glance

• Deal Value: ~$6 billion, all-cash
• Target: Terns Pharmaceuticals (NASDAQ: TERN), Foster City, CA
• Lead Asset: TERN-701 — oral, allosteric BCR-ABL inhibitor for relapsed/refractory CML
• Clinical Stage: Phase 1 CARDINAL trial (dose expansion ongoing)
• Key Clinical Data: 80% MMR rate at ≥320mg dose, 0 dose-limiting toxicities
• Terns Market Cap Pre-Deal: ~$5.3 billion
• Merck’s M&A Spend Since 2024: $25+ billion (Verona Pharma, Cidara, Terns)
• Keytruda Annual Revenue: ~$30 billion; LOE expected 2028
• Deal Status: Advanced negotiations; expected to close within days

---

Sources: Financial Times, Reuters, Fierce Pharma, Terns Pharmaceuticals IR, ASH 2025 oral presentation (Blood, 2025;146:901), OncLive, Seeking Alpha, STAT News